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ReseaRch aRticle
abstRact Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option 
in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; how-
ever, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo reporting, 
we show that continuous MEKi with intermittent CDK4/6 inhibitor (CDK4/6i) led to more complete 
tumor responses versus other combination schedules. Nevertheless, some tumors acquired resist-
ance that was associated with enhanced phosphorylation of ribosomal S6 protein. These data were 
supported by phospho-S6 staining of melanoma biopsies from patients treated with CDK4/6i plus 
targeted inhibitors. Enhanced phospho-S6 in resistant tumors provided a therapeutic window for the 
mTORC1/2 inhibitor AZD2014. Mechanistically, upregulation or mutation of NRAS was associated 
with resistance in in vivo models and patient samples, respectively, and mutant NRAS was sufficient 
to enhance resistance. This study utilizes an in vivo reporter model to optimize schedules and supports 
targeting mTORC1/2 to overcome MEKi plus CDK4/6i resistance.
SIGNIFICANCE: Mutant BRAF and NRAS melanomas acquire resistance to combined MEK and CDK4/6 
inhibition via upregulation of mTOR pathway signaling. This resistance mechanism provides the pre-
clinical basis to utilize mTORC1/2 inhibitors to improve MEKi plus CDK4/6i drug regimens. Cancer 
Discov; 8(5); 1–14. ©2018 AACR.
See related commentary by Sullivan, p. 532.
See related article by Romano et al., p. 556.
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iNtRODUctiON
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) such 
as palbociclib (PD0332991), ribociclib (LEE011), and abe-
maciclib (LY2835219) are highly selective and have gained 
FDA approval/breakthrough therapy designation in estrogen 
receptor (ER)–positive/HER2-negative breast cancer in com-
bination with aromatase inhibitors or the selective estrogen 
receptor degrader fulvestrant (1). Although immunother-
apies and BRAF/MEK–targeted inhibitors have been FDA 
approved for the treatment of advanced-stage cutaneous 
melanoma, these therapies have limitations, and more effec-
tive treatment options are still required.
Aberrant cell-cycle progression is a hallmark of cancer and 
in melanoma is driven by mutant BRAF/NRAS–mediated 
upregulation of cyclin D1, amplification of cyclin D1, and 
loss of expression of the cyclin-dependent kinase inhibitor 
p16INK4A (2). These mechanisms lead to enhanced activity 
of CDK4/6 in the early-G1 stage of the cell cycle. CDK4/6i 
treatment alone produces cytostatic effects in tumors and 
needs to be combined with other agents such as BRAF inhibi-
tors (BRAFi) and MEK1/2 inhibitors (MEKi). Trials utilizing 
CDK4/6i alone or in combination are under way in melanoma 
(3–5), but their use needs to be optimized, and mechanisms 
of acquired resistance are not known. In addition, continuous 
dosing of patients with CDK4/6i results in dose-limiting tox-
icities including neutropenia (6), and combinatorial inhibitor 
approaches can yield unique sets of toxicities. A key current 
question is how to maximize effects of CDK4/6i-based com-
binations while minimizing toxicities (3).
In vivo reporter models have been established to quantita-
tively analyze the response and resistance to targeted therapies 
selectively in the tumor and in a temporal manner (7, 8). In this 
study, we evaluated combination schedules with intermittent 
dosing of MEKi and/or CDK4/6i in vivo in melanoma models. 
We assessed combination schedules for their effects on tumor 
growth and E2F pathway inhibition. In addition, we character-
ized mechanisms of acquired resistance that arise from each 
schedule. Our studies identify resistance to MEK1/2–CDK4/6 
targeting associated with molecular alterations in NRAS and 
upregulation of ribosomal S6 protein (RPS6). These findings 
were supported by analysis of clinical trial samples. Targeting 
the resistance-associated pathway using mTORC1/2 inhibi-
tors led to enhanced apoptosis in MEKi–CDK4/6i-resistant 
cells and reduced tumor growth in vivo. Our findings provide 
new insight to scheduling and resistance to MEK1/2–CDK4/6 
targeting and provide second-line treatment strategies for 
MEKi–CDK4/6i-resistant melanoma.
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Continuous MEKi Treatment and Intermittent 
CDK4/6i Treatment Leads to Complete  
Responses In Vivo
To test optimal scheduling of MEKi plus CDK4/6i, we 
utilized a mutant BRAF 1205Lu model expressing an E2F-
driven luciferase reporter and constitutive tdTomato fluo-
rescent protein. Although continuous dosing of both drugs 
is effective in preclinical models (9), this regimen is not well 
tolerated in patients (4, 5, 10). On the basis of the inter-
mittent dosing of CDK4/6i in breast cancer trials (10), we 
designed three scheduling arms: (i) continuous MEKi with 
intermittent CDK4/6i (3 weeks on/1 week off); (ii) continu-
ous CDK4/6i with intermittent MEKi (3 weeks on/1 week 
off); and (iii) intermittent scheduling of both therapies (3 
weeks on/1 week off; Fig. 1A). Our previous studies with this 
model showed that vehicle-treated tumors reach 800 mm3 
within 25 days (9). Of the three arms, the intermittent sched-
ule of both therapies was the least effective with tumor 
regrowth during drug treatment and partial response to 
retreatment following drug holidays. By the third cycle of 
treatment (days 56–77), the majority of tumors no longer 
responded to the combination therapy, suggesting a drug-
tolerant state. More-effective tumor growth inhibition was 
observed with continuous dosing of either CDK4/6i or MEKi 
with intermittent dosing of the other drug. Of these two 
arms, continuous MEKi with intermittent CDK4/6i achieved 
statistical significance when compared with the intermit-
tent schedule arm by both tumor volume measurement and 
tdTomato detection (Fig. 1B; Supplementary Fig. S1) and 
gave more complete responses as observed by nonpalpable 
tumors (Fig. 1A). Furthermore, residual tumors showed low 
levels of proliferation markers and a high number of apop-
totic cells in the continuous MEKi intermittent CDK4/6i arm 
(Fig. 1C and D), but only a few tumors acquired resistance in 
this arm and statistical significance was not reached. Mouse 
weights were comparable across the three arms with modest 
decreases in the continuous CDK4/6i arm that reached statis-
tical significance at day 66 (Fig. 1E), consistent with toxicities 
seen in preclinical and clinical studies (10). No significant 
toxicities in the various scheduling arms were observed with 
Figure 1.  Comparison of continuous single-agent and intermittent dosing schedules in 1205Lu reporter xenografts. A, Mice bearing 1205Lu reporter 
xenografts were dosed with continuous MEKi + intermittent (3 weeks on/1 week off) palbociclib, continuous palbociclib + intermittent (3 weeks on/ 
1 week off) PD0325901, and both drugs intermittently (3 weeks on/1 week off). Number of complete responses in each individual schedule is indicated.  
B, Average tumor volume in three scheduling arms measured by digital caliper (error bars = SEM, n = 8; **, P < 0.001; *, P < 0.027). Shaded area represents 
a 1-week drug holiday (single agent or combination). (continued on following page)
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Figure 1. (Continued) C, Quantitation of Ki67-positive tumor cells taken from mice with resistant tumors (day 87) from continuous MEKi arm (n = 2), 
continuous CDK4/6i arm (n = 3), and intermittent MEKi + CDK4/6i arm (n = 6). D, Quantitation of cleaved caspase-3–positive tumor cells taken from mice 
with resistant tumors (day 87) from continuous MEKi arm (n = 2), continuous CDK4/6i arm (n = 3), and intermittent MEKi + CDK4/6i arm (n = 6). E, Average 
weight (g) of mice bearing 1205Lu xenografts treated in each cohort (n = 8, error bars, SD; *, P < 0.05).
regards to anemia and neutropenia (Supplementary Fig. S2). 
Overall, the continuous MEKi with intermittent CDK4/6i 
treatment arm was the most effective schedule with regard to 
delaying melanoma tumor growth.
E2F Reactivation Associates with Resistance
Concurrent with tumor growth analysis, we also measured 
E2F luciferase to temporally quantitate pathway activation 
status. During the 3-week MEKi plus CDK4/6i lead-in con-
sistent across all three arms, E2F activity normalized to tumor 
size was suppressed (Fig. 2A–C). The continuous MEKi-
intermittent CDK4/6i schedule gave lowest overall tumor 
growth, but two resistant tumors emerged (Fig. 2A). Tumor 
#2 showed reactivation of luciferase reporter activity during 
the first two rounds of CDK4/6i release and was dramatically 
activated during the third round of treatment associating 
E2F-regulated activity with tumor progression. Continuous 
CDK4/6i with intermittent MEKi maintained E2F activity at 
low levels; however, rapid regrowth of tumors was associated 
with E2F reactivation (Fig. 2B). In the intermittent MEKi plus 
CDK4/6i schedule, we observed rapid reactivation of the E2F 
pathway within the first drug holiday in multiple tumors (#1, 
#2, #3, and #7) that preceded tumor regrowth at day 7 of the 
drug holiday (Fig. 2C). In our previous studies, E2F levels 
did not dramatically increase in 1205Lu tumors from mice 
treated with control diet over the course of 23 days (9), thus 
suggesting that E2F reactivation is frequently associated with 
therapeutic resistance (Supplementary Fig. S3).
Differential Signaling Pattern Across  
Scheduling Arms
To investigate the resistance mechanism to MEKi–CDK4/6i 
combinations, we performed reverse-phase protein array 
(RPPA) analysis on tumor samples (11). Unsupervised hierar-
chical clustering sorted the samples into three distinct groups 
with a high degree of clustering of resistant tumors within 
each scheduling group (Fig. 3A). RPPA analysis revealed 
that continuous MEKi plus intermittent CDK4/6i–resistant 
tumors (#1 and #2) and the continuous CDK4/6i plus inter-
mittent MEKi–resistant tumor (#1) were associated with 
maintenance of the MEK–ERK1/2 pathway and phospho-S6 
levels (Fig. 3A). We validated the RPPA results by Western 
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Figure 2.  Utility of the E2F reporter system to determine efficacious schedules. A, Effect of continuous MEKi plus intermittent CDK4/6i. Longitu-
dinal quantification of firefly luminescence representing pathway activity and tdTomato fluorescence representing tumor size. B, Effect of continuous 
CDK4/6i plus intermittent MEKi. C, Effect of intermittent dosing of MEKi plus CDK4/6i.
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blot analysis. Notably, phospho-S6 levels were elevated above 
baseline of control tumors (Fig. 3B). These data implicate 
maintenance of MEK signaling and elevated S6 protein activ-
ity in acquired resistance to MEKi plus CDK4/6i.
Short Pulsatile CDK4/6 Inhibition  
Leads to Rapid Tumor Progression
To further refine drug scheduling, we compared the most 
effective arm with continuous MEKi plus pulsatile (4 days on, 
3 days off) CDK4/6i. E2F pathway activity analysis of the pul-
satile schedule showed that E2F was rapidly reactivated after 
each off-combination cycle (Supplementary Fig. S4A). Initially, 
there was no noticeable difference in tumor size between the 
two arms, but after 3 weeks of treatment, there was a clear sepa-
ration in tumor kinetics. Tumors on continuous MEKi with 
pulsatile CDK4/6i progressed more rapidly, producing only 
one complete responder compared with the continuous MEKi 
with intermittent CDK4/6i schedule (Supplementary Fig. 
S4C). Mouse weight, hematocrit levels, and neutrophil counts 
were not significantly altered with the pulsatile schedule (Sup-
plementary Figs. S2 and S4D), indicating that the schedule was 
well tolerated. These data indicate that prolonged dosing of 
CDK4/6i is more beneficial in delaying tumor growth.
Acquired Resistance to MEK and CDK4/6 
Inhibition Is Associated with Enhanced S6 
Phosphorylation
To extend the study of resistance to mutant NRAS mel-
anoma, we analyzed WM1366 xenografts (ComboR1 and 
ComboR2) that had acquired resistance to continuous MEK 
and CDK4/6 inhibitor treatment (Fig. 4A). We performed 
RNA sequencing (RNA-seq) and targeted cancer panel 
sequencing on resistant tumors. Gene set variance analysis 
revealed distinct gene expression signatures between the two 
ComboR tumors, indicating heterogeneity (Supplementary 
Fig. S5A). Pathway analysis showed that most pathways were 
not uniquely regulated between ComboR1 and ComboR2; 
however, one of the 44 shared pathways included upregu-
lation of an AKT pathway gene signature (Supplementary 
Fig. S5A and S5B). Interestingly, in ComboR1, NRAS was 
one of the most differentially upregulated genes by RNA-
seq and had the highest copy-number change by targeted 
sequencing (Supplementary Fig. S5C; Fig. 4B). We observed 
high copy-number change of NRAS in a second WM1366-
resistant tumor sample isolated from the continuous MEKi 
plus intermittent CDK4/6i schedule (Fig. 4B; Supplementary 
Fig. S5D). Furthermore, we detected high levels of NRAS in 
Figure 3.  Pathway analysis of resistant tumors. A, RPPA analysis on resistant tumors. Unsupervised hierarchical clustering sorted the tumor samples 
into three distinct groups. Intermittent #5 clustered by itself. B, Western blot validation of RPPA analysis on resistant tumor lysates.
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Figure 4.  Mutant NRAS xenografts that acquired resistance to MEKi plus CDK4/6i show induction of mTOR activity and aberrant regulation of NRAS. 
A, WM1366 xenografts acquire resistance to continuous MEK and CDK4/6 inhibition. B, Identification of copy-number variations in ComboR tumors from 
next-generation sequencing targeting of 170 genes. C, Proteins and phospho-proteins involved in the activation of the mTOR pathway by RPPA analysis 
of resistant tumors. D, MEKi- and CDK4/6i-resistant tumors show induction of AKT and RPS6 activity and enhanced expression of NRAS. E, NRAS knock-
down in ComboR1 cell line inhibits phospho-S6. Western blot analysis of cell knockdown with either control or NRAS siRNA.
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ComboR1 and elevated phosphorylated AKT and S6 protein 
in both ComboR tumors (Supplementary Fig. S5E; Fig. 4C). 
We validated the enhanced levels of NRAS, phospho-AKT, 
and phospho-S6 in ComboR1 and ComboR2 tumors com-
pared with tumors that progressed on vehicle by western blot 
analysis (Fig. 4D).
To determine whether upregulation of NRAS is required 
for enhanced phospho-S6, we silenced NRAS in resistant 
cells derived from ComboR1. Consistent with tumor samples, 
ComboR1 cells displayed high expression of NRAS compared 
with control cells (Fig. 4E). Knockdown of NRAS in ComboR1 
cells dramatically reduced phospho-S6 levels, suggesting that 
NRAS mediates increased mTOR–S6 pathway activation (Fig. 
4E). Taken together, these data indicate that distinct mecha-
nisms are employed by melanoma tumors to circumvent MEK 
plus CDK4/6 inhibition, but those resistance pathways even-
tually converge to upregulate phosphorylation of S6 protein.
High Phospho-S6 Levels Are Associated  
with CDK4/6 Inhibitor Combinations in  
Patient Samples
To determine the clinical relevance of our findings, we 
analyzed levels of S6 phosphorylation in tumor samples from 
nine patients with mutant BRAF melanoma enrolled in two 
phase Ib/II clinical trials involving the triple combination 
of BRAFi, MEKi, and CDK4/6i (see Methods). IHC staining 
indicated that high phospho-S6 levels during pretreatment 
predicted a worse clinical outcome, but patient numbers were 
low and the difference did not reach statistical significance 
(Fig. 5A). The sets contained three patient-matched pairs of 
pretreatment and posttreatment samples. Importantly, there 
was a clear increase in phosphorylated S6 in two of the three 
posttreatment samples from patients who relapsed within 
a year on the triple therapy compared with the pretreat-
ment sample (Fig. 5B). The patient sample (patient #3) with 
reduced phosphorylation of S6 posttreatment was associated 
with a prolonged response (421 days) to the triple combina-
tion (Fig. 5C).
To identify mechanisms of resistance associated with 
patients, we sequenced multiple pre- and post-CDK4/6i sam-
ples from a single patient from the LOGIC2 trial (Supple-
mentary Fig. S6). Interestingly, we found a gain in NRAS 
mutation (Q61H and Q61L) in two of the three samples iso-
lated from one patient post-CDK4/6i progression (Fig. 5D). 
To determine whether acquisition of an NRAS mutation in a 
mutant BRAF background is sufficient to modulate response 
to MEKi plus CDK4/6i, we utilized two mutant BRAF cell 
lines, WM793 and 1205Lu, exogenously expressing either 
Q61H or Q61L mutant NRAS (Fig. 5E). In both cell lines, 
constitutive expression of the mutant NRAS significantly 
decreased sensitivity of the cells to MEKi plus CDK4/6i 
(Fig. 5F). Taken together, our data suggest that upregula-
tion of NRAS activity confers resistance to MEKi–CDK4/6i 
targeting. Moreover, phospho-S6 activity may be a marker of 
response to CDK4/6i plus targeted therapy in patients.
Enhanced Phospho-S6 Levels  
Are mTORC1 Dependent
To determine whether ComboR tumors show phospho-
S6 dependency, we utilized cell lines from tumors (Fig. 6A; 
Supplementary Fig. S7A). ComboR cells in culture exhibited 
a modest preference for low doses of MEKi plus CDK4/6i 
with slightly enhanced growth rates (Fig. 6A). In the absence 
of drug, ComboR cells displayed a similar proliferative capac-
ity as control #4 cells isolated from WM1366 tumors pro-
gressing on control diet (Supplementary Fig. S7B and S7C). 
S6 phosphorylation can be regulated by multiple pathways 
(12). Treatment with either the allosteric mTORC1 inhibitor 
rapamycin, the dual mTORC1/2 kinase inhibitor AZD2014, 
or the β-sparing PI3K inhibitor GDC-0032 effectively reduced 
S6 phosphorylation in ComboR cells (Fig. 6B). BY719, a 
PI3Kα inhibitor, modestly reduced S6 phosphorylation. Fur-
thermore, knockdown of the mTORC1 component Rap-
tor diminished S6 phosphorylation, whereas depletion of 
the mTORC2 component Rictor had only modest effects 
(Fig. 6C). Treatment with either a PI3Kβ-selective inhibitor 
(TGX221), a PI3Kδ/γ inhibitor (IPI-145), an ERK1/2 inhibitor 
(SCH-772984), or a RSK inhibitor (SL0101) did not reduce S6 
phosphorylation (Fig. 6B). Together, these data suggest that 
enhanced S6 phosphorylation is mediated by the mTORC1 
complex.
Inhibition of mTOR Blocks the Growth  
of MEKi-CDK4/6i–Resistant Tumors
Given the consistent effects with mTOR inhibitors, we 
focused on this class of inhibitors and utilized AZD2014 in 
subsequent studies, as this drug induced a more complete 
inhibition of the mTOR pathway than rapamycin (Fig. 6B). 
Notably, both ComboR1 and ComboR2 cells were more sen-
sitive to AZD2014 monotherapy compared with parental and 
control cells in in vitro viability assays, suggesting a therapeu-
tic window (Fig. 7A). Next, we compared the effects of single 
agents, double combination (MEKi and CDK4/6i), or triple 
combination (MEKi, CDK4/6i, and AZD2014) in ComboR 
cells. Western blot analysis showed that AZD2014 inhibited 
phospho-S6 levels in both parental and ComboR cells but that 
the triple combination was required for efficient RB dephos-
phorylation in ComboR cells (Supplementary Fig. S8A). By 
colony formation assay, we confirmed that ComboR cells 
were more sensitive to AZD2014 alone than parental cells 
(Fig. 7B). Furthermore, the triple combination completely 
ablated colony formation in ComboR cells (Fig. 7B). Similar 
inhibitory effects were seen by inclusion of either MEKi or 
CDK4/6i alone plus AZD2014 by MTT assay (Fig. 7C; Supple-
mentary Fig. S8B). Increased apoptosis was observed with the 
triple drug treatment compared with MEKi plus CDK4/6i or 
AZD2014 alone treatments in ComboR cells, suggesting that 
combined mTORC1/2 inhibition with MEKi/CDK4/6i may 
be more effective in decreasing cell viability and inducing cell 
death (Fig. 7D). In contrast, mTORC1/2 inhibition alone did 
not induce cell death in control #4 cells (Fig. 7D).
Finally, we tested the effect of mTORC1/2 inhibition on 
MEKi–CDK4/6i-resistant xenografts. ComboR1 cells dis-
played short latency and aggressive growth in vivo compared 
with control #4 cells (Supplementary Fig. S9A). Given the 
potential for toxicity, we utilized an intermittent AZD2014 
dosing schedule (twice daily, 2 days on/5 days off) previ-
ously shown to be as efficacious as chronic daily dosing in 
xenograft models and associated with lower toxicities (13). 
We confirmed that Combo-resistant tumors were sensitive 
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Figure 5.  Increased phospho-S6 in patient samples following progression on BRAFi/MEKi/CDK4/6i. A, Kaplan–Meier survival curve of patients with 
melanoma treated with triple inhibitor combination targeting BRAF (LGX818), MEK (MEK162), and CDK4/6 (LEE011) sorted by intensity of phospho-S6 
activity in pretreatment samples. Low activity, grade 2; high activity, grade 3. PFS, progression-free survival. B and C, Immunostaining of S6 phosphoryla-
tion in poor responding and prolonged responding matched pairs of melanoma samples before and relapsed under triple inhibitor combination targeting 
BRAF (LGX818), MEK (MEK162), and CDK4/6 (LEE011). D, Oncoprint depicting alterations and comutations in pretreatment and posttreatment samples 
from a single mutant BRAF patient in the LOGIC2 trial. E, Mutant BRAF cells WM793 and 1205Lu with constitutive expression of mutant NRAS (Q61H 
and Q61L). F, Mutant BRAF cells coexpressing mutant NRAS (Q61H and Q61L) are less sensitive to MEKi and CDK4/6i (error bars = SD, n = 3, *, P < 0.05; 
**, P < 0.005; ***, P < 0.0005).
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to mTORC1/2 inhibitor alone in vivo (Fig. 7E). However, the 
tumors eventually progressed, and all mice had to be sacrificed 
within 2 weeks. No significant weight loss was observed with 
intermittent AZD2014 dosing (Supplementary Fig. S9B).
Mice bearing ComboR1 tumors treated with MEKi plus 
CDK4/6i showed similar tumor growth as those treated with 
control diet (Fig. 7F). In contrast, inclusion of intermittent 
doses of AZD2014 led to a significant suppression of tumor 
growth (Fig. 7F) and improved mouse survival (Fig. 7G). This 
was also reflected in increases in apoptotic markers, cleaved 
caspase-3 and PARP, and decreased Ki67 staining following 
triple drug treatment (Fig. 7H; Supplementary Fig. S10). 
Taken together, these data suggest that the mTOR pathway 
mediates acquired resistance to the combination of MEK and 
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CDK4/6 inhibition through the enhanced phosphorylation 
of S6, which can be blocked with an mTORC1/2 inhibitor.
DiscUssiON
The recent clinical approval of multiple CDK4/6 inhibi-
tors and frequent alterations in components of the CDK4/6 
pathway in melanoma support the rapid interrogation and 
optimization of these agents in this disease and raise ques-
tions regarding how they may be leveraged in combination 
with other targeted therapies. Using a quantitative in vivo 
reporter model to test scheduling of combinations, we show 
that continuous MEKi dosing with intermittent CDK4/6i 
yields more effective tumor inhibition than alternative inter-
mittent scheduling options. Nevertheless, some tumors ulti-
mately acquire drug resistance. Our studies demonstrate that 
this resistance is associated with aberrant regulation of NRAS 
and enhanced phosphorylation of S6 in both xenografts and 
patient samples (Supplementary Fig. S11). Taken together, 
these data suggest that mTORC1/2 inhibitors may serve as a 
salvage option for MEKi–CDK4/6i-resistant disease.
CDK4/6i lead to cytostatic effects and the addition of 
MEKi enhances tumor apoptosis in melanoma (9). How-
ever, alternative dosing schedules are required to potentially 
alleviate toxicities observed in early-phase clinical trials with 
continuous dosing of MEKi and CDK4/6i. Furthermore, 
reversible drug-tolerant states or adaptive mechanisms exist 
before the acquisition of permanent resistance and can be 
exploited (14–16). Similarly, discontinuous dosing or drug 
holidays may also present a disadvantage for cells that are 
addicted to drug (17). In our ComboR models, we observed 
a modest drug preference rather than an addiction pheno-
type in resistant cells, as these cells continue to proliferate 
in vitro and grow aggressively in vivo even in the absence of 
drug. Recent mechanistic studies involving BRAFi addiction 
show that drug holidays could benefit from a second tar-
geted inhibitor that could augment the addiction phenotype 
(18). Tumor progression in the intermittent scheduling arm 
(1-week drug holiday) was associated with rapid E2F reactiva-
tion and tumors were tolerant to subsequent retreatment. 
The best arm (continuous MEKi-intermittent CDK4/6i) 
would alleviate a major toxicity, as neutropenia induced by 
palbociclib is often reversible and resolved with a 1-week-off 
cycle (19). Our scheduling study is relevant for other tumor 
types, as combinations involving MEKi and CDK4/6i show 
promise in PDX models of mutant KRAS–driven colorectal 
cancer (20) and mutant KRAS non–small cell lung cancer 
xenografts (21).
We propose that acquired resistance to MEKi–CDK4/6i 
combination is associated with enhanced phosphorylation 
of S6. These results complement studies in other tumor 
models. PDK1, a kinase required for full activation of AKT 
and other AGC kinases, is upregulated with short-term pal-
bociclib treatment in breast cancer models (22). Also, the 
induction of metabolic activity via mTOR pathway may serve 
as a CDK4/6i resistance mechanism in pancreatic cancer (23). 
Although we did not detect alterations in Raptor associated 
with resistance, this mTORC1 component has been implicated 
in palbociclib-induced senescence (24) and our data do not 
implicate mTORC2 in resistance (Fig. 6C; ref. 25). Of note, 
PI3KCA, which is frequently mutated and can sustain cell 
proliferation via the mTORC1–S6 node (26), was wild-type in 
our posttreatment patient samples (Supplementary Fig. S12).
Mechanistically, sequencing of mutant NRAS MEKi–
CDK4/6i-resistant xenograft samples revealed heterogeneous 
genetic and transcriptomic features. For example, NRAS was 
overexpressed in two of three resistant xenografts sequenced. 
However, all three tumor samples had high phospho-S6 
levels, suggesting a common downstream node for resist-
ance and that mTOR pathway activation can be also driven 
Figure 6.  Inhibition of mTOR reduces S6 phosphorylation in ComboR cells. A, WM1366 ComboR cells are resistant to MEKi (PD’901) and CDK4/6i 
(palbociclib) in vitro by MTT assay (error bars = SD, n = 3, *, P < 0.05; **, P < 0.005; ***, P < 0.0005). Cells were treated for 7 days. B, Effects of PI3K/AKT/
mTORC1-2/ERK inhibitors (1 μmol/L) on RPS6 activity in ComboR cells. C, Effects of knockdown of mTORC1 and mTORC2 components Raptor and Rictor 
on phospho-S6 activity.
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Figure 7.  mTORC1/2 inhibitor enhances the effects of MEKi plus CDK4/6i in resistant cells. A, WM1366 ComboR cells show increased sensitivity 
to mTORC1/2 inhibitor AZD2014 compared with parental and control cells (error bars = SD, n = 3, *, P < 0.05; **, P < 0.005; ***, P < 0.0005). Cells were 
treated for 7 days and analyzed by MTT assay. B, The triple targeting of MEK, CDK4/6, and mTORC1/2 has greater efficacy in ComboR cells by colony 
formation assay. C, As per B, but MTT assays were performed (error bars = SD, n = 3, *, P < 0.05; **, P < 0.005). D, The triple targeting of MEK, CDK4/6 and 
mTOR led to increased apoptosis in ComboR cells by Annexin V staining (*, P < 0.05; **, P < 0.005). E, WM1366 ComboR1 xenografts were treated with 
vehicle or AZD2014 (20 mg/kg, 2/5 days; error bars = SEM, n = 4; vehicle, n = 5; AZD2014, *, P = 0.009). F, WM1366 ComboR1 xenografts were treated 
with control chow, combination chow (PD’901 and palbociclib), and combination chow plus AZD2014 (20 mg/kg, 2/5 days by oral gavage; error bars = 
SEM, n = 4; control, n = 4; combo, n = 3; combo+AZD2014, *, P < 0.05; **, P < 0.005). G, Kaplan–Meier curve of data in F shows significant survival  
advantage of AZD2014 inclusion in ComboR1 xenografts (P < 0.05). The endpoint for euthanasia was predetermined as 1,000 mm3 tumor volume.  
H, Analysis of downstream targets regulated by the combination chow (PD’901 and palbociclib) and combination chow plus AZD2014.
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by mechanisms other than NRAS. In CDK4/6i-progressing 
mutant BRAF patient samples, we detected NRAS mutations 
in two of three samples, pointing at heterogeneous mecha-
nisms within a single patient. It is possible that intratumoral 
heterogeneity exists within patient samples that may be cir-
cumvented with multiregion sampling (26). Our findings are 
in line with upregulation of oncogene activity as a mode of 
resistance to targeted therapies (27).
Although multiple mechanisms may exist in upregulating 
the mTOR pathway during the acquisition of resistance, impor-
tantly, the convergence upon the S6 node allows for the utility 
of AZD2014 or similar mTORC inhibitors that may serve as a 
salvage option. Unlike rapalogs, AZD2014 inhibits kinase activ-
ity of both mTORC1 and mTORC2, to induce a more complete 
inhibition of the pathway (13), and is currently in phase II trials 
for advanced solid tumors and clear cell renal cancer (28). The 
elevated S6 phosphorylation associated with resistance and 
the effect of 2-day AZD2014 treatment in preclinical models 
of resistance warrant further longitudinal studies to analyze 
the effects of the mTORC1/2 inhibitor sequencing schedules 
interlaced with MEKi–CDK4/6i therapies.
MethODs
Cell Culture
1205Lu and WM1366 cells were transduced with E2F-EGFP-firefly 
luciferase as described previously (9). 1205Lu and WM1366-reporter 
cells were cultured in MCDB153 (Sigma) with 2% FBS, 20% Leibowitz 
L-15 medium, and 5 μg/mL insulin. WM1366 and 1205Lu cells were 
donated by Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA) 
in 2005. Cell lines were authenticated by sequencing at the NRAS, 
BRAF, and CDK4 loci, and by STR analysis (completed April 2015).
Reagents
Palbociclib (PD0332991) was generously provided by Pfizer, Inc. 
PD0325901, AZD2014, rapamycin, GDC0032, BYL719, TGX221, IPI145, 
and SCH772984 were purchased from Selleck Chemicals. SL0101 was 
purchased from Millipore. Collagenase was purchased from Sigma.
Western Blot Analysis
Protein lysates were prepared in Laemmli sample buffer, sepa-
rated by SDS page, and proteins transferred to a PVDF membrane. 
Immunoreactivity was detected using horseradish protein conjugate 
secondary antibodies (CalBioTech) and chemiluminescence substrate 
(Thermo Fisher Scientific) on the Versadoc Imaging System (Bio-Rad). 
The following primary antibodies were utilized: phospho-RB1 (S780; 
#9307), RB1 (#9309), phospho-ERK1/2 (#9101), ERK1/2 (#9102), 
phospho-S6 Ribosomal Protein (S235/236; #4857), S6 (#2217), 
phospho-MEK1/2 (Ser217/221; #9121), pAKT (S473; #4060), AKT 
(#9272), HSP90 (#4877), Rictor (#2114), Raptor (#2280), cleaved 
caspase-3 (#9661), and cleaved PARP (#9541), all purchased from Cell 
Signaling Technology; NRAS (sc31 and sc519) and Fra-1 (sc605) were 
purchased from Santa Cruz Biotechnology, Inc.; actin (A2066) was 
purchased from Sigma-Aldrich Co.
RPPA Analysis
Tumors were lysed in RPPA lysis buffer and analyzed as described 
previously (9). Tumors analyzed in Figs. 3 and 4C were all isolated 
at the same time point at day 87 and the final time point shown in 
the tumor kinetics graph, respectively. All mice were kept on drug 
during the day of isolation. Comparisons of normalized RPPA data 
were performed between groups by the two-sample t test method 
with 1,000 permutations and assumed unequal variance. A P < 
0.05 and fold change >50% were used as cutoffs for determining 
significance. Unsupervised and supervised hierarchical clustering 
heat maps were produced using log2-transformed sample expression 
data for antibody lists constructed from either significance cutoffs 
or a priori pathway information. Calculations were performed using 
Matlab (v2017b).
Targeted Sequencing
Targeted sequencing was performed using the Illumina TruSight 
Tumor 170 Targeted Panel that covers all annotated coding exons 
for 170 genes implicated in cancer etiology and pathways. Sequenc-
ing libraries were prepared per the manufacturer’s recommenda-
tion. Sequencing was performed on the Illumina NextSeq 500 
platform with 2 × 100 base paired-end reads at an average depth 
of approximately 90 M reads per sample. Base calls were converted 
to FASTQ format on the Illumina cloud-based BaseSpace plat-
form. The BaseSpace TruSight Tumor 170 App Version 1.0.1 was 
then used to align reads to the human reference genome version 
hg19 with the Isaac Aligner, perform local realignment around 
indel calls, call small variants using the Illumina Pisces algorithm, 
and detect deletions/amplifications using the Illumina CRAFT 
(CNV Robust Analysis For Tumors) copy number variant caller. 
Variant call annotation was performed using ANNOVAR software 
version 2017jun01 (29). An unsupervised hierarchical clustering 
heat map was generated from CRAFT amplification and deletion 
copy-number variation call data for alterations found in at least 
one drug-resistant sample. The targeted sequencing results have 
been deposited in the NCBI Sequence Read Archive (SRA) database 
under accession number SRP133305.
siRNA Transfection
Cells were transfected as described previously (9). NRAS-specific 
siRNA (#D-003919-02) sequence is as follows: CAAGUGUGAUU 
UGCCAACA. Raptor-specific siRNA (#D-004107-01-0005) sequence 
is as follows: GAAACCAUCGGUGCAAAUU. Rictor-specific siRNA 
(#D-016984-01-0005) specific sequence is as follows: UCAACGAG 
CUCACAUAUGA.
Melanoma Patient Samples
Patient studies were conducted according to the Declaration of 
Helsinki, and informed consent was obtained from all patients. 
Tumor samples were collected and analyzed according to University 
of Zurich Institutional Review Board–approved protocols (EK647 
and EK800). Patient samples were collected from the following trials. 
For NCT01543698, BRAFi and MEKi (LGX818 and MEK162) were 
administered on a continuous schedule and CDK4/6i (LEE011) was 
administered in a 3-week-on, 1-week-off schedule. For NCT02159066 
(LOGIC2), patients progressing on BRAFi and MEKi (LGX818 and 
MEK162) were treated with CDK4/6i (LEE011).
Sequencing of Patient Samples
One patient from the LOGIC2 trial (NCT02159066) had tumor 
biopsies collected before combination therapy, during encorafenib 
and binimetinib therapy, and after encorafenib, binimetinib, and 
ribociclib triple combination therapy (informed consent obtained; 
protocol number: EK647 and EK800). Melanoma cell cultures were 
established from the biopsies and submitted for targeted panel 
sequencing. Samples were subjected to 150 bp paired-end sequencing 
on an Illumina HiSeq4000. Raw reads were trimmed for adaptors and 
quality by trimmomatic (30) and aligned with bwa mem (31). Aligned 
reads were processed by the GATK best practices for somatic muta-
tion calling (version 3.7; ref. 32), and variants were annotated with 
the Variant Effect Predictor (33).
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IHC Analysis of Patient Samples for Phospho-S6
Sections were stained with anti–phospho-S6 (Ser235/236; antibody 
#4858 from Cell Signaling Technology). For quantitation of the slides, 
five to six representative areas per slide were analyzed using Aperio 
eSlide Manager software in a blinded manner by a board-certified 
pathologist (K. HooKim). To generate the patient survival curve, grad-
ing scores of pretreatment samples were based on the following readout: 
grade 3 >80% positive, grade 2 >40%–80% positive, grade 1 = 1%–40%.
IHC Analysis for Ki67 and Cleaved Caspase-3
Tissue were fixed in formalin and paraffin embedded. Sections 
were stained with anti-Ki67 (1:150) and cleaved caspase-3 (1:300) 
antibody. The intensity of staining and the percentage of positive 
cells were evaluated in a blinded manner using the Aperio ScanScope 
XT slide scanning system, and quantification was done with the 
Aperio eSlide Manager software. Five representative areas (×200 
magnification) per slide were analyzed. Ki67 antibody (MA1-90584) 
was purchased from Thermo Fisher Scientific, and cleaved caspase-3 
antibody (#9661) was purchased from Cell Signaling Technology.
In Vivo Experiments
All studies were reviewed and approved by the Institutional Animal 
Care and Use Committee at Thomas Jefferson University (Philadel-
phia, PA). For scheduling studies, mice bearing 1205Lu reporter xen-
ografts (50–100 mm3) were fed with combination chow (AIN-76A diet 
with 7 mg/kg PD0325901 and 429 mg/kg palbociclib, n = 8.cohort) 
for 3 weeks and then switched to single agent (AIN-76A with 429 mg/
kg palbociclib or AIN-76A with 7 mg/kg PD0325901) or control diet 
(AIN-76A) for one week. For therapeutic window studies, mice bear-
ing WM1366 control #4 or ComboR1 xenografts were fed with control 
diet or control diet plus AZD2014 administered by oral gavage bi-daily 
(2 days on, 5 days off). AZD2014 was dissolved in DMSO to a final 
concentration of 20 mg/kg. Control and combination chow arms 
received DMSO alone by oral gavage. For triple combination study, 
mice with WM1366 ComboR1 xenografts were fed with either con-
trol diet, combination chow, or combination chow plus AZD2014. 
AZD2014 was administered by oral gavage bi-daily (2 days on, 5 days 
off) for the first week then once daily, twice a week for the second 
week. Digital caliper and firefly luciferase measurements were carried 
out as described previously (9).
Generation of Resistant Lines
Combination PD0325901- and palbociclib-resistant lines were gen-
erated from WM1366 xenograft tumors. Resistant tumors were iso-
lated, and cells were dissociated using collagenase and continuously 
cultured in the presence of low-dose PD0325901 and palbociclib.
Annexin V Staining
After indicated treatments, cells were resuspended in binding 
buffer and stained with Annexin V-APC for 15 minutes. Apoptotic 
cells were analyzed by flow cytometry on the LSRII (BD Biosciences). 
Data were analyzed using FlowJo software (TreeStar Inc.).
MTT Assay
Analysis was carried out as described previously (9). At indicated 
time points, thiazolyl blue tetrazolium bromide (Sigma) was added 
to growth medium, incubated for 4 hours, and then solubilized over-
night with 10% SDS/0.1 N HCl.
Statistical Analysis
In vitro data were analyzed using a two-tailed t test assuming 
unequal variance, with error bars representing SD. In vivo statistical 
analysis is described in Supplementary Materials and Methods.
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